GlaxoSmithKline (NYSE: GSK)’s investigational once daily extended release formulation of Lamictal® (lamotrigine) - Lamictal® XR™ - has been found effective as add-on treatment in patients with partial epilepsy with and without secondary generalization.
Currently, Lamictal® XR™ is being developed for the treatment of epilepsy and once approved will become the first extended release, new generation epilepsy treatment taken once-daily.
The finding abovementioned was derived from data of two clinical trials recently presented at the American Academy of Neurology (AAN) meeting.
According to Dean Naritoku, M.D., Professor of Neurology and Pharmacology, Southern Illinois University, Springfield, IL.:
"These data are important because they show that the extended release formulation of Lamictal reduces the frequency of seizures. The once daily dosing regimen may also provide a more convenient treatment option for patients.
In addition, when compared to Lamictal immediate release, given twice a day, the new investigational formulation demonstrated fewer daily fluctuations in serum concentration and more stable blood levels over time."
Being suffered by more than three million Americans of all ages (according to the Epilepsy Foundation), epilepsy is defined by recurrent unprovoked seizures and is a change in sensation, awareness, or behavior brought about by an electrical disturbance in the brain.
Read the full report.
Comment Preview